cIEF of glycoproteins in short nanoporous channels

描述（由申请人提供）：迫切需要能够在生物标志物发现中实现更高通量的新技术。 医学上有丰富的癌症候选蛋白质生物标志物，但缺乏临床验证的生物标志物。 原因是发现方法的通量非常低，通常由于统计数字小而给出错误的指示。糖型的靶向搜索对于发现癌症的蛋白质生物标志物是有希望的。 我们建议，以确定3毫米的通道挤满了无孔二氧化硅的快速等电聚焦的免疫提取的蛋白质从血清中的糖型的可行性。这些通道具有96孔格式，可无缝集成到从血清到检测的全自动分析中，每天可对数千份血清样品进行表征。 选择前列腺特异性抗原（PSA）作为模型蛋白，因为有已发表的证据表明，等电聚焦可以解析对癌症具有更高特异性的糖型，并且该生物标志物有丰富的数据和血清样本。 我们已经与临床肿瘤学家建立了合作关系，从前列腺癌患者中获得人类血清样本，以测试这项技术的可行性。 公共卫生相关性：将开发新技术以提高新癌症诊断的发现率。

DESCRIPTION (provided by applicant): New technology to enable higher throughput in biomarker discovery is urgently needed. Medicine is rich in protein biomarker candidates for cancer, but poor in clinically validated biomarkers. The reason is that the methods for discovery are very low in throughput, usually giving false indications due to the statistics of small numbers Targeted searches of glycoforms are promising for the discovery of protein biomarkers for cancer. We propose to determine the feasibility of 3-mm channels packed with nonporous silica for rapid isoelectric focusing of the glycoforms of an immunoextracted protein from serum. These channels have a 96-well format for seamless integration into a fully automation analysis, from serum to detection, enabling thousands of serum samples per day to be characterized. Prostate specific antigen (PSA) is chosen as the model protein because there is published evidence that isoelectric focusing can resolve glycoforms with higher specificity for cancer, and there is a wealth of data and serum samples for this biomarker. We have established a collaboration with a clinical oncologist to obtain human serum samples from prostate cancer patients for testing the feasibility of this technology. PUBLIC HEALTH RELEVANCE: New technology will be developed to increase the discovery rate for new cancer diagnostics.